CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.12.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
04.12.17	Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer (Businesswire)
20.11.17	Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy (Businesswire)
13.11.17	Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 (Businesswire)
08.11.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
07.11.17	FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN (Businesswire)
01.11.17	Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting (Businesswire)
01.11.17	Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting (Businesswire)
04.10.17	Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer (Businesswire)
04.10.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
07.09.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
05.09.17	Cellectis to Participate in Upcoming Investor Conferences (Businesswire)
05.09.17	Cellectis Reports Clinical Hold of UCART123 Studies (Businesswire)
17.08.17	Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center (Businesswire)
02.08.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
02.08.17	Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 (Businesswire)
25.07.17	Cellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering (Businesswire)
24.07.17	Cellectis Granted Patent for CRISPR Use in T-Cells (Businesswire)
20.07.17	Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering (Businesswire)
10.07.17	Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million (Businesswire)
27.06.17	First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital (Businesswire)
23.06.17	Calyxt Files Registration Statement for Proposed Initial Public Offering (Businesswire)
23.01.17	Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions (Businesswire)
22.11.16	Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016 (Businesswire)
21.11.16	Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY (Businesswire)
15.11.16	Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123 (Businesswire)
07.11.16	Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting (Businesswire)
31.10.16	Cellectis Hosts World’s First Gene Edited Dinner in NYC (Businesswire)
04.10.16	Cellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014 (Businesswire)
27.09.16	Cellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare (Businesswire)
08.09.16	Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results (Businesswire)
27.06.16	MIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year (Businesswire)
27.06.16	Cellectis Named 2016 Technology Pioneer by the World Economic Forum (Businesswire)
20.06.16	Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) (Businesswire)
19.05.16	Cellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016 (Businesswire)
11.05.16	Cellectis Reports First Quarter 2016 Financial Results (Businesswire)
02.05.16	Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting (Businesswire)
21.03.16	Cellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc. (Businesswire)
16.03.16	Cellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies (Businesswire)
08.03.16	Cellectis Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7-9, 2016 (Businesswire)
02.03.16	Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility (Businesswire)
19.01.16	Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies (Businesswire)
11.01.16	Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions (Businesswire)
07.01.16	Cellectis Announces Chief Medical Officer Appointment to Senior Leadership Team (Businesswire)
23.12.15	Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies (Businesswire)
21.12.15	Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016 (Businesswire)
03.12.15	Cellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier (Businesswire)
30.11.15	Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
19.11.15	Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies (Businesswire)
16.11.15	Cellectis Reports Third Quarter and First Nine Months 2015 Financial Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten